To have a sense of comparison, in PsA patients with inadequate response to TNF inhibitors, at 6 months, the ACR20 response was achieved by ustekinumab, a IL-12/23 inhibitor, in 35.6% of patients vs 14.5% in the placebo group,9 and by secukinumab, an IL-17 inhibitor, in 45.5% of patients vs 14.3% in the placebo group.10 Infections, including herpes zoster, major adverse cardiovascular events, neutropenia, lymphopenia, and elevation of transaminases were observed in the tofacitinib group of patients and should be monitored in subsequent studies. Here, TNF is linked to infection.